IRWD
Ironwood Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.26
−0.70%Aug 6, 2026, 20:04 UTC
Ironwood Pharmaceuticals started enrollment in its confirmatory Phase III study of apraglutide.
Source:Aug 6, 2026, 00:00 UTC
Ironwood Pharmaceuticals reported Q2 2026 total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million, with LINZESS US net sales of $282 million for the quarter.
Aug 6, 2026, 00:00 UTC
Ironwood Pharmaceuticals repaid $200 million principal of its convertible notes.
Source: